← All trials
NCT05292001
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 2, 2022
- Primary completion
- Apr 1, 2024
- Completion date
- Apr 1, 2024
- First posted
- Mar 23, 2022
- Last posted
- Oct 6, 2022
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oregon Health and Science UniversityLead sponsor
- Oregon Health and Science UniversityOverall official - principal investigator
- Oregon Health and Science UniversityReponsible party - principal investigator
- Collins Medical TrustCollaborator
- Oregon Health and Science UniversitySponsor investigator
- Oregon Health and Science UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.